InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | 2026-04-01 | Frost Mark T | Chief Financial Officer | Purchase | 5,000 | $5.00 | $25K | 17.5K | View ↗ | |
| 2026-03-17 | 2026-03-18 | DENELSKY STEPHEN J | Director | Purchase | 10.0K | $4.87 | $49K | 21.0K | View ↗ | |
| 2026-03-17 | 2026-03-18 | Snider William | Director | Purchase | 8,475 | $4.85 | $41K | 32.0K | View ↗ | |
| 2026-03-16 | 2026-03-18 | Snider William | Director | Purchase | 12.5K | $4.99 | $62K | 23.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | $86.5M-8.1% | $94.1M-16.1% | $112.3M-1.0% | $113.3M |
| Cost of revenues | $36.6M-6.9% | $39.4M-14.7% | $46.2M-12.1% | $52.5M |
| Gross profit | $49.9M-8.9% | $54.8M-17.1% | $66.1M+8.6% | $60.8M |
| Sales and marketing expenses | $19.2M-13.5% | $22.2M-7.7% | $24.1M-3.9% | $25.0M |
| General and administrative expenses | $17.7M-17.5% | $21.5M-5.6% | $22.8M-7.1% | $24.5M |
| Research and development expenses | $8.8M-15.2% | $10.4M-11.5% | $11.8M-4.6% | $12.3M |
| Amortization of acquired intangible assets | $4.0M-23.4% | $5.3M-4.9% | $5.5M | — |
| Goodwill impairment - Note 5 | $48.0M | $0 | — | — |
| Other operating expenses - Note 2 | $729K-54.7% | $1.6M+2169.0% | $71K | — |
| Total operating expenses | $98.5M+61.5% | $61.0M-5.0% | $64.2M-5.3% | $67.8M |
| Operating loss | -$48.6M-682.2% | -$6.2M | — | — |
| Interest expense | -$4.9M-39.1% | -$3.5M+1.5% | -$3.6M-40.9% | -$2.5M |
| Loss on pension settlement - Note 8 | -$1.2M | $0 | — | — |
| Loss on equity securities - Note 12 | $0+100.0% | -$1.6M-152.1% | -$632K | — |
| Other expense, net | -$2.7M-717.2% | -$325K | — | — |
| Total other expense | -$8.8M-61.5% | -$5.5M-22.6% | -$4.5M-98.1% | -$2.2M |
| Loss before income taxes | -$57.4M-392.0% | -$11.7M-356.4% | -$2.6M+72.2% | -$9.2M |
| Income tax (benefit) expense | -$686K-192.7% | $740K | — | — |
| Net loss | -$56.7M-357.1% | -$12.4M-263.3% | -$3.4M+64.1% | -$9.5M |
| Basic and diluted loss per share (in dollars per share) | -$1K-357.1% | -$280-250.0% | -$80+65.2% | -$230 |
| Basic and diluted (in shares) | $44.4M+2.0% | $43.5M+2.6% | $42.4M+2.4% | $41.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 Expectations
Harvard Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation
Harvard Bioscience Inc (HBIO) Q4 2025 Earnings Call Highlights: Strong Operational Efficiency ...